STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference being held virtually from April 17-20, 2023.
Details of the event are as follows:
Fireside Chat Date and Time: Tuesday, April 18, 2023, at 2:15 p.m. ET
The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Collegium Pharmaceutical, Inc.
Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contact:
Christopher James, M.D.
Vice President, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Marissa Samuels
Vice President, Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$27.01 |
| Daily Change: | -0.01 -0.04 |
| Daily Volume: | 218,397 |
| Market Cap: | US$871.070M |
March 27, 2025 March 17, 2025 February 27, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
